Shingles vaccine (Zostavax®): patient group direction (PGD) template
- Public Health England
- Part of:
- Immunisation patient group direction (PGD) templates
- First published:
- 14 July 2015
- Last updated:
- 23 August 2016, see all updates
PGD template to support the national shingles (Zostavax®) vaccination programme for eligible adults: September 2016 to August 2017.
Ref: Publications Gateway Reference: 2015185 MS Word Document, 147KB
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
This patient group direction (PGD) template is to support the shingles (herpes zoster, live) vaccination programme provided via NHS England commissioners. It is valid from 1 September 2016 to 31 August 2017.
This PGD template requires further authorisation by an appropriate authorising person, relating to the class of person by whom product is to be supplied, in accordance with the Human Medicines Regulations 2012 (HMR). This may be a clinical governance or patient safety lead, who has designated responsibility for signing PGDs on behalf of the authorising body. The PGD is not legal or valid without signed authorisation in accordance with HMR 2012 schedule 16 part 2
Adoption and governance of the use of this PGD is the responsibility of the authorising organisation and provider.
Provider organisations, health professionals and immunisation practitioners should check they are working to the current PGD versions and only work to documents authorised in accordance with HMR 2012 schedule 16 part 2.
Published: 14 July 2015
Updated: 23 August 2016
- Updated patient group direction template valid up to 31 August 2017
- Updated PGD to allow for intramuscular administration (in line with the amended product license).
- Updated the shingles PGD to include detailed information on the use of the shingles vaccine in immunosuppressed individuals.
- First published.